Grace Therapeutics (GRCE) Competitors $3.20 +0.14 (+4.58%) As of 09/5/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GRCE vs. BDTX, MCRB, NVCT, FTLF, KYTX, GLSI, ELDN, CTOR, MIST, and MOLNShould you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Black Diamond Therapeutics (BDTX), Seres Therapeutics (MCRB), Nuvectis Pharma (NVCT), FitLife Brands (FTLF), Kyverna Therapeutics (KYTX), Greenwich LifeSciences (GLSI), Eledon Pharmaceuticals (ELDN), Citius Oncology (CTOR), Milestone Pharmaceuticals (MIST), and Molecular Partners (MOLN). These companies are all part of the "pharmaceutical products" industry. Grace Therapeutics vs. Its Competitors Black Diamond Therapeutics Seres Therapeutics Nuvectis Pharma FitLife Brands Kyverna Therapeutics Greenwich LifeSciences Eledon Pharmaceuticals Citius Oncology Milestone Pharmaceuticals Molecular Partners Grace Therapeutics (NASDAQ:GRCE) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation. Do analysts recommend GRCE or BDTX? Grace Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 275.00%. Black Diamond Therapeutics has a consensus target price of $11.67, suggesting a potential upside of 296.83%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Grace Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Do insiders & institutionals hold more shares of GRCE or BDTX? 6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 11.1% of Grace Therapeutics shares are owned by company insiders. Comparatively, 6.0% of Black Diamond Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer GRCE or BDTX? In the previous week, Black Diamond Therapeutics had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 5 mentions for Black Diamond Therapeutics and 2 mentions for Grace Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.11 beat Grace Therapeutics' score of -0.17 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grace Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Black Diamond Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is GRCE or BDTX more profitable? Black Diamond Therapeutics' return on equity of 12.70% beat Grace Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Grace TherapeuticsN/A -20.36% -18.09% Black Diamond Therapeutics N/A 12.70%9.58% Which has better valuation & earnings, GRCE or BDTX? Grace Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrace TherapeuticsN/AN/A-$9.57M-$0.86-3.72Black Diamond TherapeuticsN/AN/A-$69.68M$0.2312.78 Which has more volatility & risk, GRCE or BDTX? Grace Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 2.93, suggesting that its stock price is 193% more volatile than the S&P 500. SummaryBlack Diamond Therapeutics beats Grace Therapeutics on 12 of the 14 factors compared between the two stocks. Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRCE vs. The Competition Export to ExcelMetricGrace TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.25M$3.18B$5.83B$9.93BDividend YieldN/A2.27%6.70%4.52%P/E Ratio-3.7221.1076.1526.11Price / SalesN/A466.44562.61123.62Price / CashN/A45.7236.9959.28Price / Book0.669.8711.486.09Net Income-$9.57M-$53.42M$3.29B$266.51M7 Day Performance5.61%2.93%1.27%0.46%1 Month Performance7.74%9.85%7.94%4.59%1 Year PerformanceN/A15.74%62.94%26.04% Grace Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRCEGrace Therapeutics2.0545 of 5 stars$3.20+4.6%$12.00+275.0%N/A$44.25MN/A-3.72N/AHigh Trading VolumeBDTXBlack Diamond Therapeutics3.442 of 5 stars$2.87-0.3%$11.67+306.5%-47.3%$163.97MN/A12.4890News CoveragePositive NewsAnalyst ForecastMCRBSeres Therapeutics3.0169 of 5 stars$18.80+1.6%$73.67+291.8%+7.6%$161.96M$126.32M-4.09330NVCTNuvectis Pharma3.2478 of 5 stars$6.52+2.7%$15.33+135.2%+8.4%$161.65MN/A-5.578News CoverageFTLFFitLife Brands3.1432 of 5 stars$18.43+7.3%$23.00+24.8%+12.0%$161.34M$64.47M21.9420Analyst UpgradeKYTXKyverna Therapeutics2.7667 of 5 stars$3.63-2.4%$16.60+357.3%-48.0%$160.87M$7.03M-0.9996GLSIGreenwich LifeSciences1.1588 of 5 stars$10.97-4.9%$42.00+282.9%-18.2%$157.16MN/A-8.073ELDNEledon Pharmaceuticals2.01 of 5 stars$2.61+0.8%$10.00+283.1%+5.4%$155.09MN/A-2.2310News CoverageAnalyst ForecastAnalyst RevisionCTORCitius Oncology0.878 of 5 stars$1.87-5.1%$3.00+60.4%+0.0%$154.39MN/A0.00N/AGap DownMISTMilestone Pharmaceuticals1.623 of 5 stars$1.78flat$5.00+180.9%+23.3%$151.29M$1M-2.1230Positive NewsMOLNMolecular Partners1.7541 of 5 stars$3.57-4.0%$8.00+124.1%-38.1%$150.19M$5.65M-1.72180News CoverageAnalyst ForecastGap Up Related Companies and Tools Related Companies Black Diamond Therapeutics Alternatives Seres Therapeutics Alternatives Nuvectis Pharma Alternatives FitLife Brands Alternatives Kyverna Therapeutics Alternatives Greenwich LifeSciences Alternatives Eledon Pharmaceuticals Alternatives Citius Oncology Alternatives Milestone Pharmaceuticals Alternatives Molecular Partners Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRCE) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored3 Major A.I. Threats That Could Upend the U.S. EconomyThe media's calling Artificial Intelligence a "revolution," but for many Americans, the real impact might actu...Goldco Precious Metals | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
